Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 12, 2012

View Archived Issues

Pilot trial evaluates rebamipide in aspirin-induced small bowel damage

Japanese study supports in vivo antitumor activity of Golgi-disrupting agent

Xenon Pharmaceuticals enters alliance for pain therapeutics

Sangamo BioSciences begins two phase II trials in HIV

JNK inhibitor prevents hearing loss due to transient cochlear ischemia in preclinical study

Researchers describe role of Th17 cells in vaccine-induced immunity

Chinese company patents new receptor tyrosine kinase inhibitors

Janssen Pharmaceutica patents novel antifungal agents

Baxter submits supplemental BLA to FDA for Gammagard Liquid

Isis Pharmaceuticals reports phase I data on ISIS-TTRRx

University of Arkansas discloses novel vaccine vectors for Campylobacter infections

Tetragenetics flu vaccine protects against H5N1 in preclinical study

HGS provides pipeline update and goals for 2012

Novel serine/threonine-protein kinase PAK inhibitors patented by Afraxis

Guilin Sanjin Pharmaceutical claims novel saponins

Celtaxsys obtains anti-inflammatory drug from Estrellita Pharmaceuticals

Akinion begins treatment in phase I/II AKN-028 study

Scientists at Gene Signal disclose new peptides for wound healing

Lexicon Pharmaceuticals reports topline data from LX-4211/sitagliptin combination trial

Forma Therapeutics enters into exclusive alliance

EC adopts opinion on pioglitazone-containing drugs

Akebia Therapeutics spin-out company created

Biocon reports phase III data on immunotherapy for chronic plaque psoriasis

Cynapsus Therapeutics reports encouraging first-in-human data on APL-130277

Kadmon acquires anticancer candidate from Concordia Pharmaceuticals

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...